ES2483896T3 - Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen - Google Patents
Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen Download PDFInfo
- Publication number
- ES2483896T3 ES2483896T3 ES03785958.4T ES03785958T ES2483896T3 ES 2483896 T3 ES2483896 T3 ES 2483896T3 ES 03785958 T ES03785958 T ES 03785958T ES 2483896 T3 ES2483896 T3 ES 2483896T3
- Authority
- ES
- Spain
- Prior art keywords
- breast cancer
- hydroxy tamoxifen
- prevention
- medication
- sine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 6
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 6
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract 1
- 102000000872 ATM Human genes 0.000 abstract 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 abstract 1
- 102000036365 BRCA1 Human genes 0.000 abstract 1
- 108700020463 BRCA1 Proteins 0.000 abstract 1
- 101150072950 BRCA1 gene Proteins 0.000 abstract 1
- 102000052609 BRCA2 Human genes 0.000 abstract 1
- 108700020462 BRCA2 Proteins 0.000 abstract 1
- 101150008921 Brca2 gene Proteins 0.000 abstract 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 abstract 1
- 206010012186 Delayed delivery Diseases 0.000 abstract 1
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000003349 gelling agent Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45896303P | 2003-04-01 | 2003-04-01 | |
| US458963P | 2003-04-01 | ||
| PCT/EP2003/015029 WO2004087123A1 (en) | 2003-04-01 | 2003-12-15 | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2483896T3 true ES2483896T3 (es) | 2014-08-08 |
Family
ID=33131847
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03785958.4T Expired - Lifetime ES2483896T3 (es) | 2003-04-01 | 2003-12-15 | Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen |
| ES08103014.0T Expired - Lifetime ES2456958T3 (es) | 2003-04-01 | 2003-12-15 | Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen |
| ES08103007.4T Expired - Lifetime ES2456957T3 (es) | 2003-04-01 | 2003-12-15 | Tratamiento de cáncer de seno con 4-hidroxitamoxifen |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08103014.0T Expired - Lifetime ES2456958T3 (es) | 2003-04-01 | 2003-12-15 | Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen |
| ES08103007.4T Expired - Lifetime ES2456957T3 (es) | 2003-04-01 | 2003-12-15 | Tratamiento de cáncer de seno con 4-hidroxitamoxifen |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7704516B2 (https=) |
| EP (3) | EP1608353B1 (https=) |
| JP (1) | JP5490346B2 (https=) |
| AU (1) | AU2003294973B2 (https=) |
| CA (1) | CA2519980C (https=) |
| ES (3) | ES2483896T3 (https=) |
| IL (1) | IL170807A (https=) |
| MX (1) | MXPA05010597A (https=) |
| NO (1) | NO333805B1 (https=) |
| NZ (1) | NZ542499A (https=) |
| WO (1) | WO2004087123A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004054557A2 (en) * | 2002-12-18 | 2004-07-01 | Laboratoires Besins International | Treatment of mastalgia with 4-hydroxy tamoxifen |
| JP4684655B2 (ja) * | 2002-12-18 | 2011-05-18 | ラボラトワール ブザン アンテルナスィヨナル | ４−ヒドロキシタモキシフェンによる乳房密度低下 |
| CA2519980C (en) * | 2003-04-01 | 2012-04-10 | Laboratoires Besins International | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| US7767717B2 (en) * | 2003-06-09 | 2010-08-03 | Ascend Therapeutics, Inc. | Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
| US7968532B2 (en) * | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| CN1946387B (zh) * | 2004-03-22 | 2011-08-31 | 法国法杏大药厂 | 4-羟基三苯氧胺在制备治疗和预防良性乳房疾病的药物中的应用 |
| US7507769B2 (en) | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP1579857A1 (en) * | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Chemically stable compositions of 4-hydroxy tamoxifen |
| EP1579856A1 (en) * | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP1799201B1 (en) * | 2004-10-14 | 2008-11-26 | Laboratoires Besins International | 4-hydroxy tamoxifen gel formulations |
| EP1647271A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
| EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
| US10080760B2 (en) * | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
| WO2015175561A1 (en) | 2014-05-12 | 2015-11-19 | Quest Diagnostics Investments Incorporated | Quantitation of tamoxifen and metabolites thereof by mass spectrometry |
| KR101571098B1 (ko) | 2014-07-16 | 2015-11-23 | 건국대학교 산학협력단 | 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물 |
| EP3230478B1 (en) | 2014-12-12 | 2023-08-02 | Miradx | Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors |
| JP7131773B2 (ja) * | 2016-04-29 | 2022-09-06 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ホルモン受容体に関連する転写活性の標的尺度 |
| IL304863B2 (en) | 2017-09-11 | 2025-08-01 | Atossa Therapeutics Inc | Methods for making and using endoxifen |
| US20210299094A1 (en) * | 2018-07-24 | 2021-09-30 | Cornell University | Methods of upregulating tiparp as anticancer strategies |
| JP7662204B2 (ja) | 2019-07-03 | 2025-04-15 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| WO2025019830A1 (en) * | 2023-07-19 | 2025-01-23 | Atossa Therapeutics, Inc. | Anti-tumor compounds and methods of use thereof and synthesis thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2558373B1 (fr) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
| ATE80152T1 (de) * | 1987-04-21 | 1992-09-15 | Heumann Pharma Gmbh & Co | Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en. |
| US5045553A (en) | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
| DE3836862A1 (de) | 1988-10-27 | 1990-05-03 | Schering Ag | Mittel zur transdermalen applikation von steroidhormonen |
| US5189212A (en) | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
| TW218849B (https=) * | 1991-05-17 | 1994-01-11 | Bristol Myers Squibb Co | |
| US5613958A (en) | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
| DE4407742C1 (de) | 1994-03-08 | 1995-06-22 | Hexal Pharma Gmbh | Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat |
| US5720963A (en) * | 1994-08-26 | 1998-02-24 | Mary Kay Inc. | Barrier disruption treatments for structurally deteriorated skin |
| ES2156361T5 (es) * | 1996-03-29 | 2012-12-26 | Keyvest Gmbh | Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis" |
| EP1043986B1 (en) | 1997-12-23 | 2003-04-16 | Hexal Ag | Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin |
| US6013270A (en) * | 1998-04-20 | 2000-01-11 | The Procter & Gamble Company | Skin care kit |
| CA2393762A1 (en) | 1999-12-16 | 2001-06-21 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
| DE10033853A1 (de) | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20030175329A1 (en) | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
| PT1317921E (pt) | 2001-12-07 | 2009-11-06 | Besins Mfg Belgium | Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações |
| JP4684655B2 (ja) * | 2002-12-18 | 2011-05-18 | ラボラトワール ブザン アンテルナスィヨナル | ４−ヒドロキシタモキシフェンによる乳房密度低下 |
| WO2004054557A2 (en) | 2002-12-18 | 2004-07-01 | Laboratoires Besins International | Treatment of mastalgia with 4-hydroxy tamoxifen |
| CA2519980C (en) | 2003-04-01 | 2012-04-10 | Laboratoires Besins International | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| US7767717B2 (en) | 2003-06-09 | 2010-08-03 | Ascend Therapeutics, Inc. | Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
| US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| EP1579857A1 (en) | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Chemically stable compositions of 4-hydroxy tamoxifen |
| US7507769B2 (en) | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP1579856A1 (en) | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP1647271A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
-
2003
- 2003-12-15 CA CA2519980A patent/CA2519980C/en not_active Expired - Lifetime
- 2003-12-15 WO PCT/EP2003/015029 patent/WO2004087123A1/en not_active Ceased
- 2003-12-15 ES ES03785958.4T patent/ES2483896T3/es not_active Expired - Lifetime
- 2003-12-15 EP EP03785958.4A patent/EP1608353B1/en not_active Expired - Lifetime
- 2003-12-15 MX MXPA05010597A patent/MXPA05010597A/es active IP Right Grant
- 2003-12-15 JP JP2004570040A patent/JP5490346B2/ja not_active Expired - Lifetime
- 2003-12-15 EP EP08103014.0A patent/EP1941871B1/en not_active Expired - Lifetime
- 2003-12-15 EP EP08103007.4A patent/EP1952810B1/en not_active Expired - Lifetime
- 2003-12-15 ES ES08103014.0T patent/ES2456958T3/es not_active Expired - Lifetime
- 2003-12-15 NZ NZ542499A patent/NZ542499A/en not_active IP Right Cessation
- 2003-12-15 US US10/734,638 patent/US7704516B2/en not_active Expired - Lifetime
- 2003-12-15 AU AU2003294973A patent/AU2003294973B2/en not_active Expired
- 2003-12-15 ES ES08103007.4T patent/ES2456957T3/es not_active Expired - Lifetime
-
2005
- 2005-09-12 IL IL170807A patent/IL170807A/en active IP Right Grant
- 2005-09-30 NO NO20054526A patent/NO333805B1/no not_active IP Right Cessation
-
2009
- 2009-01-14 US US12/353,890 patent/US8475814B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1119950A1 (en) | 2009-03-20 |
| EP1952810A1 (en) | 2008-08-06 |
| WO2004087123A1 (en) | 2004-10-14 |
| US20090186944A1 (en) | 2009-07-23 |
| US20050031695A1 (en) | 2005-02-10 |
| US7704516B2 (en) | 2010-04-27 |
| IL170807A (en) | 2014-08-31 |
| HK1086193A1 (en) | 2006-09-15 |
| CA2519980C (en) | 2012-04-10 |
| ES2456957T3 (es) | 2014-04-24 |
| NO20054526L (no) | 2005-09-30 |
| EP1608353B1 (en) | 2014-04-30 |
| EP1941871A1 (en) | 2008-07-09 |
| EP1941871B1 (en) | 2014-01-08 |
| NZ542499A (en) | 2008-10-31 |
| JP5490346B2 (ja) | 2014-05-14 |
| EP1608353A1 (en) | 2005-12-28 |
| JP2006514967A (ja) | 2006-05-18 |
| MXPA05010597A (es) | 2006-03-09 |
| AU2003294973B2 (en) | 2010-05-13 |
| NO333805B1 (no) | 2013-09-16 |
| EP1952810B1 (en) | 2014-01-08 |
| CA2519980A1 (en) | 2004-10-14 |
| US8475814B2 (en) | 2013-07-02 |
| ES2456958T3 (es) | 2014-04-24 |
| AU2003294973A1 (en) | 2004-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2483896T3 (es) | Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen | |
| Hirakawa et al. | Surgical site infection in clean-contaminated head and neck cancer surgery: risk factors and prognosis | |
| McCullough et al. | Vitamin D, cod liver oil, sunshine, and phototherapy: Safe, effective and forgotten tools for treating and curing tuberculosis infections—A comprehensive review | |
| Nappi et al. | Hyaluronic acid: a valid therapeutic option for early management of genitourinary syndrome of menopause in cancer survivors? | |
| Kini et al. | An unusual occurrence of epidermoid cyst in the buccal mucosa: a case report with review of literature | |
| BRPI0411079A (pt) | composições farmacêuticas compreendendo atorvastatina, fabricadas sem granulação | |
| BR0013222A (pt) | Medicamento para aplicação tópica, uso de um xanteno halogenado, composição farmacêutica para administração tópica, e, método de tratamento | |
| JP2006514967A5 (https=) | ||
| Souza et al. | Endonyx toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye | |
| Poddar et al. | Newer therapies in dermatophytosis | |
| Nason et al. | Bacterial biofilms may explain chronicity in osteoradionecrosis of the temporal bone | |
| US20060013862A1 (en) | Onychomycosis: a new process for cure | |
| Hadi et al. | Multifunctional dynamic toolbox: cordycepin plays a therapeutic role in various disorders | |
| Sekhon | Iodine: A support against infections and emerging as an antibiotic. | |
| Hananel et al. | Case report: recurrent Salmonella typhi chest wall abscess associated with a pituitary macroadenoma | |
| Valeriani et al. | Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy | |
| Mykola | THE SPINAL CORD SCIATIC NERVE SEGMENTAL CENTERS: PECULIARITIES OF BLOOD-NEURAL BARRIER REARRANGEMENT IN PACLITAXEL-INDUCED NEUROPATHY AND ITS CORRECTION | |
| AR028611A1 (es) | Sistema terapcutico transcutrneo con reduccion de la tendencia a la cristalizacinn de sustancia activa | |
| Goosmann et al. | Treating sinonasal crusting and infection after palatal and sinonasal cancer resection with topical antibiotic irrigations | |
| Gingrass et al. | Commentary on: Preliminary Outcomes of Hypochlorous Acid as an Adjunct for Pocket Irrigation in Revision Aesthetic Breast Surgery | |
| ES2308744T3 (es) | Utilizacion del gluconato de zinc para el tratamiento de hidradenita supurada. | |
| Bae et al. | Mucoepidermoid carcinoma in the mandible: review of a case | |
| Guozhong | Joseph Needham and Rewi Alley's China complexes | |
| Altememy et al. | The In Vitro Cytotoxicity, Hemolysis Assay and Protein Corona Studies of Silk Fibroin-Coated Mesoporous Silica Nanoparticles for Tioguanine Targeting to Leukemia | |
| PE20070701A1 (es) | Terapia contra el cancer con estrogeno |